HSDT Stock Overview A neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Helius Medical Technologies, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Helius Medical Technologies Historical stock prices Current Share Price US$0.48 52 Week High US$9.50 52 Week Low US$0.37 Beta 1.59 1 Month Change 4.42% 3 Month Change -41.16% 1 Year Change -93.14% 3 Year Change -99.83% 5 Year Change -99.97% Change since IPO -100.00%
Recent News & Updates
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for Its Portable Neuromodulation Stimulator Device Nov 19
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study Oct 01
Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Aug 10
Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 07
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke Jun 18
Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024 Jun 05 See more updates
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for Its Portable Neuromodulation Stimulator Device Nov 19
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study Oct 01
Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Aug 10
Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 07
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke Jun 18
Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024 Jun 05
Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts May 23
Helius Medical Technologies, Inc. to Report Q1, 2024 Results on May 13, 2024 May 12
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center Apr 25 Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering. Apr 16
Helius Medical Technologies Receives Written Notice from the Nasdaq Stock Market Apr 07
Helius Medical Technologies, Inc. to Report Q4, 2023 Results on Mar 28, 2024 Mar 16
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke Mar 14
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients Feb 06
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital Jan 11
Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023 Nov 11
Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy(TM) Helps Patients with Traumatic Brain Injury Return to Work Nov 07
Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023 Nov 05
Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023 Nov 04
Helius Medical Technologies, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria Sep 06
Helius Medical Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023 Aug 11
Helius Medical Technologies, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 03
Helius Medical Technologies, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting Feb 16
Helius Medical Technologies, Inc. Provides Revenue Guidance for the fourth quarter and Full Year Ended December 31, 2022 Jan 25
Helius Medical Technologies, Inc. Provides Revenue Guidance for the Forth Quarter and Full Year Ended December 31, 2022 Jan 24 Helius Medical Technologies, Inc. Reports Impairment Results for the Quarter Ended September 30, 2022
Helius Medical Technologies, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 02
Helius Medical Technologies Receives Non-Compliance Notice from Nasdaq Sep 24
Helius Medical Technologies: A Net-Net Meme Stock In The Making Aug 23
Helius Medical Technologies, Inc. Provides Revenue Guidance for the Third Quarter for 2022 Aug 17
Helius Medical Technologies, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 11
Helius Medical Technologies stock slides 51% after pricing $18M securities offering Aug 05
Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy Jul 13
Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS® Jun 02
Helius Medical Technologies, Inc. Provides Earnings Guidance for the Second Quarter of 2022 May 13
Helius Medical Technologies, Inc. to Report Q1, 2022 Results on May 12, 2022 May 04
Helius Medical Technologies, Inc. Introduces Device in U.S. to Help Multiple Sclerosis Patients Improve Walking Ability Apr 27
Helius Medical Technologies, Inc., Annual General Meeting, May 23, 2022 Apr 23
Helius Medical Technologies, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2021 Jan 28
Helius Medical Technologies, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC Sep 03
Helius Medical Technologies Announces Voluntary De-Listing from Toronto Stock Exchange Aug 26
Second quarter 2021 earnings released: US$2.58 loss per share (vs US$2.90 loss in 2Q 2020) Aug 18
We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully Aug 18
Consensus revenue estimates fall to US$333.0k Aug 17
Helius Medical makes CEO, CFO appointments Jun 15
Helius Medical Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021 May 19
Helius Medical Technologies, Inc. Not Providing Earnings Guidance for 2021, Due to COVID-19 May 18
Helius Medical Technologies, Inc. Appoints Sherrie Perkins to the Board of Directors Mar 13
Helius Medical Technologies, Inc. Not to Provide Formal Financial Outlook for the Full Year 2021 At This Time Mar 12
Full year 2020 earnings released: US$11.80 loss per share (vs US$12.99 loss in FY 2019) Mar 12
Revenue and earnings beat expectations Mar 12
Helius Medical Technologies, Inc. to Report Q4, 2020 Results on Mar 10, 2021 Feb 03
Helius Medical Technologies, Inc. has completed a Composite Units Offering in the amount of $9.599981 million. Feb 02
Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards Jan 20
Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the Ponstm Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis Jan 12
Helius Medical Technologies announces reverse stock split Dec 31
Revenue beats expectations, earnings disappoint Nov 15
Third quarter 2020 earnings released: US$0.077 loss per share Nov 15
Helius Medical Technologies EPS beats by $0.01, beats on revenue Nov 12
Helius Medical Technologies, Inc. to Report Q3, 2020 Results on Nov 12, 2020 Nov 05
Helius Medical Technologies, Inc. announced that it has received $3.44419 million in funding from Maple Leaf Investments and other investors Oct 27
Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights Oct 15
Helius Medical Technologies, Inc. Announces CEO Changes Aug 26
Helius Medical Technologies, Inc. Unable to Estimate the Duration and Impact of the COVID-19 Pandemic on its Financial and Operating Results for the Full Year 2020 Aug 24
Earnings released Aug 14
Helius Medical Technologies, Inc. to Report Q2, 2020 Results on Aug 12, 2020 Aug 11 Shareholder Returns HSDT US Medical Equipment US Market 7D -10.1% -3.4% -3.5% 1Y -93.1% 9.0% 22.1%
See full shareholder returns
Return vs Market: HSDT underperformed the US Market which returned 24% over the past year.
Price Volatility Is HSDT's price volatile compared to industry and market? HSDT volatility HSDT Average Weekly Movement 20.6% Medical Equipment Industry Average Movement 7.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: HSDT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HSDT's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company’s product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Helius Medical Technologies, Inc. was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Show more Helius Medical Technologies, Inc. Fundamentals Summary How do Helius Medical Technologies's earnings and revenue compare to its market cap? HSDT fundamental statistics Market cap US$1.82m Earnings (TTM ) -US$8.86m Revenue (TTM ) US$502.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HSDT income statement (TTM ) Revenue US$502.00k Cost of Revenue US$518.00k Gross Profit -US$16.00k Other Expenses US$8.84m Earnings -US$8.86m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.38 Gross Margin -3.19% Net Profit Margin -1,764.74% Debt/Equity Ratio 0%
How did HSDT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 11:45 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Helius Medical Technologies, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Anthony Vendetti Maxim Group Steven Lichtman Oppenheimer & Co. Inc. Andre Uddin Research Capital Corporation
Show 1 more analysts 
